Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
Status:
Completed
Trial end date:
2018-07-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of ruxolitinib at different
dose levels in combination with decitabine and the effectiveness of ruxolitinib in
combination with decitabine in patients with accelerated or blast phase Myeloproliferative
Neoplasm (MPN), which is a group of diseases of the bone marrow in which excess cells are
produced. Ruxolitinib is a drug that is approved by the Federal Drug Administration (FDA) for
the treatment of patients with advanced forms of myelofibrosis. It inhibits the Jak proteins
that are often abnormal in MPN. A recent clinical study showed that ruxolitinib treatment
could put some patients with this disease into remission. Decitabine is a chemotherapy,
approved by the Federal Drug Administration (FDA), that has been used to treat acute
leukemia. It works in some patients, but most patients with accelerated and blastic MPN do
not respond to treatment. Ruxolitinib and decitabine will be combined in this study to find
out what dose of the two medicines are safe together. Using Ruxolitinib in combination with
Decitabine is experimental. The investigators want to find out what effects, good and/or bad
it has on the patient and the disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
John Mascarenhas
Collaborators:
Incyte Corporation Myeloproliferative Disorders-Research Consortium National Cancer Institute (NCI)